Gene Therapy Manufacturers Are Highly Sought Acquisition Targets
Scale And Outsourcing Demands Lead To A Spree In Acquisitions
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Gene therapy dominated the top December deals, with a $2.9bn alliance between Roche and Saretpta for DMD treatment SRP9001, and Astellas's $3bn acquisition of Audentes Therapeutics. Follow-on public offerings made up close to or more than half of both biopharma and device financing.